Welcome to our dedicated page for Madrigal Pharmac SEC filings (Ticker: MDGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Madrigal Pharmaceuticals, Inc. filings document the company’s biopharmaceutical business, commercial reporting for Rezdiffra (resmetirom), and governance matters tied to its Nasdaq-listed common stock. Current reports include quarterly results furnished under Item 2.02, updates on Rezdiffra net sales and cash resources, and Regulation FD disclosures related to pipeline and licensing activity in MASH.
Other filings cover material agreements affecting Rezdiffra intellectual property and royalties, including amendments to a research, development and commercialization agreement, as well as proxy disclosures for director classes, board matters, executive compensation and equity incentive plans. The filing record also documents stockholder meeting proposals and corporate-governance actions for a commercial-stage biopharmaceutical company developing metabolic liver-disease therapies.
Madrigal Pharmaceuticals General Counsel Kelley Shannon T reported multiple sales of common stock on 08/18/2025. The Form 4 shows a series of dispositions across eight reported transactions, including a 458-share sale to cover tax withholding related to RSU vesting and seven sales executed under a Rule 10b5-1 trading plan adopted November 7, 2024. Reported weighted-average prices for the 10b5-1 sales range roughly from $369.02 to $376.64 per share. Following these transactions the reporting person’s beneficial ownership declined from 10,019 shares to 9,173 shares.
Madrigal Pharmaceuticals, Inc. (MDGL) Form 144 notice reports a proposed sale of securities by a person for whose account shares vested as restricted stock units. The filer plans to sell two lots of Common Stock through Morgan Stanley Smith Barney LLC on 08/18/2025: 458 shares (aggregate market value $169,386.72) and 846 shares (aggregate market value $312,884.64). Both lots were acquired on 08/15/2025 by vesting of restricted stock units from the issuer. The filing states there were no sales by the filer in the prior three months and includes the required attestation about material nonpublic information.
Madrigal Pharmaceuticals (MDGL) Form 144 filing shows a proposed sale of 2,000 common shares to be executed through Morgan Stanley Smith Barney on 08/18/2025 with an aggregate market value of $764,481.20. The filer states these 2,000 shares were acquired the same day by exercise of options under a registered plan and paid in cash. The filing also discloses that the same person sold 4,100 shares on 08/15/2025 for gross proceeds of $1,503,481.48. The filer signs a representation that they are unaware of any undisclosed material adverse information about the issuer.
Kenneth Bate, a director of Madrigal Pharmaceuticals, filed a Form 4 reporting transactions on 08/15/2025. The filing shows an acquisition of 10,000 common shares at a price of $16.46, and contemporaneous sales totaling 10,000 shares in multiple transactions at weighted-average prices ranging from about $362.87 to $368.98. Following these trades, the reporting person’s direct beneficial ownership moved from 12,627 shares immediately after the acquisition to 2,627 shares after the sales. The Form also discloses a stock option with a $16.46 exercise price covering 10,000 underlying shares, which the filer states are fully vested and exercisable.
Madrigal Pharmaceuticals (MDGL) reported a Form 144 notice for the proposed sale of 4,100 shares of common stock through Morgan Stanley Smith Barney LLC on 08/15/2025. The filing lists an aggregate market value of $1,503,481.48 based on the transaction and shows 22,289,014 shares outstanding for the issuer. The shares were acquired and are being sold on the same date by exercise of options under a registered plan and payment was made in cash. The filer reports nothing to report for securities sold during the past three months and includes the standard attestation that the seller is not aware of undisclosed material adverse information.
Madrigal Pharmaceuticals (MDGL) filed a Form 144 reporting a proposed sale of 10,000 common shares through Morgan Stanley Smith Barney on 08/15/2025 on NASDAQ with an aggregate market value of $3,652,008.00. The filer states the shares were acquired the same day by exercise of options under a registered plan and paid in cash. The filing reports 22,289,014 shares outstanding, and shows no securities sold by the filer in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Janus Henderson Group plc reports beneficial ownership of 2,191,753 shares of Madrigal Pharmaceuticals common stock, representing 9.9% of the class. The filing breaks this down by reporting persons and subsidiaries: JHIUS may be deemed the beneficial owner of 2,173,828 shares (9.8%), and the reporting tables show shared voting and shared dispositive power over 2,191,753 shares with no sole voting or dispositive power.
The filer certifies these holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing also includes a power of attorney authorizing named compliance officers to execute required ownership reports on the company’s behalf.
Paul A. Friedman, a director of Madrigal Pharmaceuticals (MDGL), exercised a stock option for 129,172 shares at an exercise price of $9.45 and on 08/13/2025 sold those shares pursuant to a Rule 10b5-1 trading plan adopted March 14, 2025. The sales were executed in multiple transactions at weighted-average prices reported in tranches with ranges from $357.70 to $374.60. As a result of these transactions, Mr. Friedmans reported direct beneficial ownership declined from 316,336 shares to 187,164 shares. He also reports indirect ownership of 655,540 shares through SQN LLC (with the customary disclaimer regarding beneficial ownership). The option shares are reported as fully vested and exercisable.
Paul A. Friedman, a director of Madrigal Pharmaceuticals (MDGL), reported option exercises on 08/11/2025 and 08/12/2025 to acquire 3,203 and 43,605 shares, respectively, at an exercise price of $9.45 per share, and contemporaneous sales of those shares under a Rule 10b5-1 trading plan adopted March 14, 2025.
The sales were executed at weighted average prices ranging approximately from $350.00 to $359.87 per share, for a total of 46,808 shares sold. Following the reported transactions the reporting person’s direct beneficial ownership is 187,164 shares and he disclaims beneficial ownership of 655,540 shares held indirectly by SQN LLC (of which he and his spouse are managing members). The underlying options were fully vested and exercisable. The form was signed by attorney-in-fact Mardi Dier on 08/13/2025.
Rebecca Taub, a director of Madrigal Pharmaceuticals, reported stock option exercises and subsequent sales on August 11 and August 12, 2025. The filing shows she exercised options to acquire 3,200 shares on 08/11/2025 and 43,263 shares on 08/12/2025 at an exercise price of $9.45 per share, and then sold those shares under a Rule 10b5-1 trading plan adopted March 14, 2025.
The report lists total shares sold of 46,463 and weighted-average sale prices reported in the footnotes ranging between $350.00 and $359.78. Following these reported transactions the filing shows Ms. Taub with 461,044 shares directly beneficially owned and an indirect interest of 655,540 shares held by SQN LLC, of which she and her spouse are managing members.